Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
13-valent pneumococcal conjugate vaccine (Beijing Zhifei Lvzhu)
- Development stage
- Unknown
- Lead developer
- Zhifei Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 13-valent pneumococcal conjugate vaccine (PCV13) developed by Beijing Zhifei Lvzhu Biopharmaceutical is a biologic vaccine designed for active immunization against pneumococcal disease caused by Streptococcus pneumoniae. It consists of purified capsular polysaccharides from 13 distinct serotypes of S. pneumoniae, each covalently conjugated to a carrier protein, such as diphtheria toxoid or tetanus toxoid, to enhance immunogenicity by inducing a T-cell dependent immune response. This formulation is intended to prevent invasive pneumococcal disease and pneumococcal pneumonia. In clinical research, it has been utilized as a comparator to evaluate the safety and immunogenicity of higher-valency candidates, including the company's 26-valent pneumococcal conjugate vaccine (PCV26).
- Other names
- Zhifei Lvzhu PCV1313-valent pneumococcal conjugate vaccine
Beyond the preview
Go deeper on 13-valent pneumococcal conjugate vaccine (Beijing Zhifei Lvzhu).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 13-valent pneumococcal conjugate vaccine (Beijing Zhifei Lvzhu).